SLC35A2 and prostate cancer: The UGT family amplification we observed significantly with higher rate in Sardinia prostate cancers comparing to prostate cancer in 10 prostate landscape studies as PRAD (MSKCC/DFCI2018), Prostate (SU2C2019), Prostate (TCGA), Prostate (SU2C), Prostate (MSKCC2010), Prostate (FHCRC,2016), Prostate (MSKCC2014), MSK-IMPACT Prostate, Prostate (Broad/Comell2012), Prostate (Eur Urol2017) (fisher test, p value <0.001).